Get started
Author

Jade M. van Berge Henegouwen

Observed names: Berge Henegouwen, J.M. van, J M Van Berge Henegouwen, J. M. van Berge Henegouwen, J. Maxime van Berge Henegouwen, J. van Berge Henegouwen, J.M. van Berge Henegouwen, Jade M van Berge Henegouwen, Jade Maxime van Berge Henegouwen, van Berge Henegouwen, J. Maxime
Observed institutions: Leiden University, Leiden University Medical Center, Erasmus MC, The Netherlands Cancer Institute, Center for Personalized Cancer Treatment, Oncode Institute
ORCID: 0000-0002-4112-9105
Observed ORCID: 0000-0002-4112-9105
OpenAlex ID: A5076722344
The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
2019 · D. L. van der Velden, L. R. Hoes, et al. · Nature · 259
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
2022 · Louisa R. Hoes, Jade M. van Berge Henegouwen, et al. · Clinical Cancer Research · 85
PDF
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
2019 · S.B. van Waalwijk van Doorn-Khosrovani, A. Pisters-van Roy, et al. · Annals of Oncology · 39
PDF
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D‐CDK4 /6 pathway alterations in the Dutch DRUP and Australian MoST trials
2023 · Laurien J. Zeverijn, Eleonora J. Looze, et al. · International Journal of Cancer · 28
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
2022 · J.M. van Berge Henegouwen, M. Jebbink, et al. · European Journal of Cancer · 27
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours
2023 · Birgit S. Geurts, Thomas W. Battaglia, et al. · BMC Cancer · 13
PDF
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy
2024 · Birgit S Geurts, Laurien J Zeverijn, et al. · The Journal of Pathology · 10
PDF
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature
2022 · J. M. van Berge Henegouwen, H. van der Wijngaart, et al. · Cancer Chemotherapy and Pharmacology · 8
PDF
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
2024 · Laurien J. Zeverijn, Birgit S. Geurts, et al. · Clinical Cancer Research · 7
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)
2025 · K. Verkerk, L.J. Zeverijn, et al. · ESMO Open · 5
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
2024 · Birgit S. Geurts, Laurien J. Zeverijn, et al. · Clinical Cancer Research · 4
Efficacy and predictors of response of nivolumab in treatment-refractory MSI solid tumors: Results of a tumor-agnostic DRUP cohort.
2023 · Birgit Geurts, Laurien Joanna Zeverijn, et al. · Journal of Clinical Oncology · 4
Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
2023 · Laurien Joanna Zeverijn, Eleonora Looze, et al. · Journal of Clinical Oncology · 4
Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
2024 · Jade M. van Berge Henegouwen, Laurien J. Zeverijn, et al. · Clinical Cancer Research · 2
1261P Trastuzumab/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: Results of a DRUP trial cohort
2021 · J. van Berge Henegouwen, M. Jebbink, et al. · Annals of Oncology · 2
PDF
594P The Drug Rediscovery Protocol (DRUP): Results of the first 500 treated patients
2020 · L.R. Hoes, H. van der Wijngaart, et al. · Annals of Oncology · 2
PDF
A more restrictive use of quinolones in patients with community acquired pneumonia is urgently needed.
2017 · J M Van Berge Henegouwen, G H Groeneveld, et al. · PubMed · 2
1710P Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
2023 · L.J. Zeverijn, J.M. van Berge Henegouwen, et al. · Annals of Oncology · 1
PDF
Supplementary Figure from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
2023 · Louisa R. Hoes, Jade M. van Berge Henegouwen, et al. · 1
124P Durvalumab in advanced, pre-treated microsatellite instability-high solid tumors: Results of a tumor-agnostic DRUP trial cohort
2022 · B.S. Geurts, T. Battaglia, et al. · Annals of Oncology · 1
Olaparib monotherapy in pretreated patients with BRCA1/2 alterations: Results of a DRUP trial cohort.
2020 · Hanneke van der Wijngaart, Louisa Rose Hoes, et al. · Journal of Clinical Oncology · 1
Data from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
2024 · Laurien J. Zeverijn, Birgit S. Geurts, et al.
Supplementary Table S4 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
2024 · Laurien J. Zeverijn, Birgit S. Geurts, et al.
Supplementary Table S1 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
2024 · Laurien J. Zeverijn, Birgit S. Geurts, et al.
Supplementary Figure S1 from The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
2024 · Laurien J. Zeverijn, Birgit S. Geurts, et al.
Works count: 86
Citation count: 505
H-index: 8
I10-index: 7
Year
Topic
Type